These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16987834)

  • 41. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 42. Stem cell transplantation: a treatment option for severe systemic sclerosis?
    van Laar JM; Farge D; Tyndall A
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii35-8. PubMed ID: 19022811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current approaches to the management of early active diffuse scleroderma skin disease.
    Nihtyanova SI; Denton CP
    Rheum Dis Clin North Am; 2008 Feb; 34(1):161-79; viii. PubMed ID: 18329538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
    Ozgen M; Koca SS; Isik A; Ozercan IH
    J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571
    [No Abstract]   [Full Text] [Related]  

  • 45. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Global improvement of systemic scleroderma under long-term administration of octreotide.
    Descamps V; Duval X; Crickx B; Bouscarat F; Coffin B; Belaich S
    Eur J Dermatol; 1999 Sep; 9(6):446-8. PubMed ID: 10491499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. D-penicillamine in systemic sclerosis? Yes!
    Medsger TA; Lucas M; Wildy KS; Baker C
    Scand J Rheumatol; 2001; 30(4):192-4. PubMed ID: 11578011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetic of antirheumatic treatments: clinical implications.
    Ferraccioli G; Tolusso B; De Santis M
    Pharmacogenomics J; 2007 Feb; 7(1):2-9. PubMed ID: 16702980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical approach to the therapy of systemic sclerosis.
    Czirják L
    Z Rheumatol; 2004 Dec; 63(6):451-6. PubMed ID: 15605208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclosporine in the treatment of an unusual case of juvenile systemic sclerosis.
    al-Mayouf SM; Silverman ED; Feldman BM; Thorner P; Laxer RM
    J Rheumatol; 1998 Apr; 25(4):791-3. PubMed ID: 9558187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of methotrexate in patients with scleroderma and mixed connective tissue disease.
    Kowal-Bielecka O; Distler O
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S160-3. PubMed ID: 21044452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis.
    Verrecchia F; Wang Y; Vija L; Farge D
    Expert Rev Clin Immunol; 2009 Jan; 5(1):35-43. PubMed ID: 20476898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progressive systemic sclerosis.
    Medsger TA
    Clin Rheum Dis; 1983 Dec; 9(3):655-70. PubMed ID: 6360519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.
    Holmberg LA; Furst DE; McSweeney PA; Nash RA
    J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826
    [No Abstract]   [Full Text] [Related]  

  • 55. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
    Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
    J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of systemic sclerosis].
    van den Hoogen FH
    Z Rheumatol; 2006 Jul; 65(4):306, 308-10. PubMed ID: 16819640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Systemic sclerosis: symptomatic treatment].
    Dziankowska-Bartkowiak B; Waszczykowska E; Skretkowicz K
    Pol Merkur Lekarski; 2003 Sep; 15(87):259-62. PubMed ID: 14679853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature.
    Derk CT; Jimenez SA
    J Rheumatol; 2003 Jul; 30(7):1616-20. PubMed ID: 12858467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
    Mittal G; Udwadia Z; Joshi VR
    J Rheumatol; 2003 May; 30(5):1121-2; author reply 1122. PubMed ID: 12734923
    [No Abstract]   [Full Text] [Related]  

  • 60. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.
    Hunzelmann N; Moinzadeh P; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Olski TM; Pfeiffer C; Riemekasten G; Schulze-Lohoff E; Sunderkoetter C; Weber M;
    Arthritis Res Ther; 2009; 11(2):R30. PubMed ID: 19261182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.